EPCAM and neoplasm: However, combination with co-stimulatory αCD28 BiMAb recognizing HER2, EpCAM, EGFR or PD-L1 significantly enhanced the anti-tumor immune response compared to no-antibody controls as well as to single treatment with αHER2–αCD3.